Lv3
211 积分 2022-04-12 加入
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
3小时前
待确认
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
4小时前
已完结
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
5小时前
已完结
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
19天前
已完结
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
19天前
已完结
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
19天前
已完结
2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults
27天前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
1个月前
已完结
Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib
3个月前
已完结
皖公网安备34019202002308
